<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358344</url>
  </required_header>
  <id_info>
    <org_study_id>P06558</org_study_id>
    <nct_id>NCT01358344</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)</brief_title>
  <official_title>A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine if SCH 530348 2.5 mg tablets containing a high
      percentage of drug as the free base are equivalent to tablets with the standard percentage
      when given to participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to 72 hours (AUC[0-72h]) of SCH 530348</measure>
    <time_frame>Up to 72 hours after SCH 530348 dose on Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal plasma concentration (Cmax) of SCH 530348</measure>
    <time_frame>Up to 72 hours after SCH 530348 dose on Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Up to 2 weeks after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard Percentage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Percentage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg delayed‑release tablet administered orally in the morning of Days 1-7</description>
    <arm_group_label>Standard Percentage</arm_group_label>
    <arm_group_label>High Percentage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 530348 (high percentage)</intervention_name>
    <description>2.5 mg tablet containing ~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5</description>
    <arm_group_label>High Percentage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 530348 (standard percentage)</intervention_name>
    <description>2.5 mg tablet containing ~23% API as free base (STANDARD) administered orally on the morning of Day 5</description>
    <arm_group_label>Standard Percentage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body Mass Index (BMI) between 18 and 32, inclusive

          -  Clinical laboratory tests within normal limits

          -  Free of any clinically significant disease that would interfere with the study
             evaluations

          -  Screening 12-lead electrocardiogram (ECG) conduction intervals within gender-specific
             normal range

          -  Vital sign measurements within the following ranges: oral body temperature, 35.0°C to
             37.5°C; systolic blood pressure, 90 to 140 mmHg; diastolic blood pressure, 45 to 90
             mmHg; pulse rate, 40 to 100 beats per minute

          -  Female participants must be postmenopausal, surgically sterile, abstinent, or using
             medically accepted method of contraception for 3 months prior to the screening period,
             during the trial, and for 2 months after stopping the trial. Non-vasectomized men must
             agree to use acceptable contraception or to abstain from sexual intercourse during the
             trial and for 3 months after stopping the medication

        Exclusion Criteria:

          -  Female participants who are pregnant, intend to become pregnant (within 3 months of
             ending the study), or are breastfeeding

          -  History of coagulation disorder(s), thrombocytopenia, bleeding tendency, ulcers, or
             gastrointestinal bleeding

          -  History of cardiac abnormalities including clinically relevant ECGs, frequent
             palpitations or syncopal episodes

          -  Any surgical or medical condition that might significantly alter the absorption,
             distribution, metabolism or excretion of any drug

          -  History of any infectious disease within 4 weeks prior to drug administration

          -  Positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus (HIV)

          -  Positive screen for drugs with a high potential for abuse

          -  History of alcohol or drug abuse in the past 2 years

          -  Blood donation in the past 60 days

          -  Previous treatment with SCH 530348

          -  Currently participating in another clinical study or has participated in a clinical
             study within 30 days

          -  Demonstrated allergic reactions

          -  Smokes more than 10 cigarettes or equivalent tobacco use per day

          -  History of malignancy

          -  Has received any protocol-defined treatment which could interfere with ability to
             participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

